research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
Search
for
Sort by
Research
960-990 / 1000+ results 
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Machine learning for nanozyme development in anti‐inflammatory applications
Rational design strategies are crucial for developing effective nanozymes for anti-inflammatory uses.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Inhibition of rat α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
research ANTI‐ANDROGENS IN HIRSUTISM
Cyproterone acetate effectively treats hirsutism and related conditions.
research A dramatic case of diabetic gustatory hyperhidrosis successfully treated with topical glycopyrrolate
Topical glycopyrrolate lotion helped reduce excessive sweating from eating in a diabetic man.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Re: Inhibitors of 5α-Reductase-Related Side Effects in Patients Seeking Medical Care for Sexual Dysfunction
research LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
Biosimilars lower costs but don't significantly improve access.
research Synthesis of 4-amidinoimidazoles incorporating a cyanamide moiety : novel precursors for biologically important purines
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research The risk of dementia with the use of 5 alpha reductase inhibitors
Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
research Nonsurgical Facial Esthetic Procedures
Nonsurgical facial treatments are becoming more popular due to their natural-looking results and minimal invasiveness.
research Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
research Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Many drugs can cause lipid metabolism issues, and labels need better warnings.
![Benzo[c]quinolizin-3-ones Theoretical Investigation: SAR Analysis and Application to Untested Compounds](/images/research/6712367a-949f-47c7-a756-2bfe6316fc69/small/15331.jpg)
research Benzo[c]quinolizin-3-ones Theoretical Investigation: SAR Analysis and Application to Nontested Compounds
The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives
research The lowest effective dose of botulinum toxin in detrusor sphincter dyssynergia
The lowest effective dose of Botox for detrusor sphincter dyssynergia is between 75-100 units.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Formononetin: A Pathway to Protect Neurons
Formononetin may help protect the brain and treat neurological diseases.
research Issues in the Treatment of Epilepsy
Treating epilepsy is complex, requiring careful drug choice and patient adherence to manage seizures and side effects.
research [Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
research Supplementary Material for: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS OF MEDICAL THERAPIES FOR LICHEN PLANOPILARIS.
Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
research Iatrogenic Cushing’s syndrome post intralesional triamcinolone acetonide in Oral submucous fibrosis: 2 case reports
Two patients got Cushing's syndrome after treatment with Triamcinolone Acetonide for mouth fibrosis, but recovered after stopping the treatment.
research Acitretin-induced alopecia areata: a case report
Acitretin can cause eyebrow and eyelash hair loss.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
research 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis
Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.